Agreements reached under this partnership
The impact of this matter on the Company’s results is expected to be limited. However, as the business offers high-value-added products for medical facilities, primarily veterinary hospitals, it is expected to make a significant contribution to the Company’s results over the medium to long term as one of its core product businesses.
| Item | Details |
|---|---|
| Impact on Business Performance | The impact of this matter on the Company’s results is expected to be limited. However, as the business offers high-value-added products for medical facilities, primarily veterinary hospitals, it is expected to make a significant contribution to the Company’s results over the medium to long term as one of its core product businesses. |
Items this document does not state (22)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Preparations to restart the factory have been completed for the chitin nanofiber business transferred to the Company on 28 April 2026. The Company aims to pursue further potential for the business as a pillar of its biomaterials operations by promoting the adoption of its products in the veterinary medical field and expanding their applications in human medicine.